Cowen and Company reiterated their outperform rating on shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) in a research report released on Friday. Cowen and Company currently has a $27.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $20.00.

Several other analysts have also commented on the stock. Piper Jaffray Companies raised shares of Intra-Cellular Therapies from a neutral rating to an overweight rating and increased their price target for the company from $14.00 to $33.00 in a research report on Thursday, September 7th. JMP Securities raised shares of Intra-Cellular Therapies from a market perform rating to an outperform rating and set a $24.00 price target for the company in a research report on Thursday, August 24th. Leerink Swann raised shares of Intra-Cellular Therapies from a market perform rating to an outperform rating in a research report on Wednesday, August 23rd. ValuEngine raised shares of Intra-Cellular Therapies from a strong sell rating to a sell rating in a research report on Friday, August 18th. Finally, Zacks Investment Research raised shares of Intra-Cellular Therapies from a hold rating to a buy rating and set a $12.00 price target for the company in a research report on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $27.11.

Shares of Intra-Cellular Therapies (ITCI) opened at 20.90 on Friday. The company’s market capitalization is $907.56 million. The firm’s 50-day moving average is $13.70 and its 200-day moving average is $12.79. Intra-Cellular Therapies has a 1-year low of $7.85 and a 1-year high of $45.20.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.33. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.03 million. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The company’s quarterly revenue was down 52.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.71) earnings per share. Analysts forecast that Intra-Cellular Therapies will post ($2.36) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies Inc. (ITCI) Stock Rating Reaffirmed by Cowen and Company” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/12/intra-cellular-therapies-inc-itci-stock-rating-reaffirmed-by-cowen-and-company.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Trexquant Investment LP acquired a new position in shares of Intra-Cellular Therapies during the first quarter valued at about $384,000. BB Biotech AG increased its holdings in shares of Intra-Cellular Therapies by 22.2% during the first quarter. BB Biotech AG now owns 1,925,000 shares of the biopharmaceutical company’s stock valued at $31,281,000 after acquiring an additional 350,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after acquiring an additional 186,165 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Intra-Cellular Therapies by 5.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 137,975 shares of the biopharmaceutical company’s stock valued at $2,243,000 after acquiring an additional 7,335 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Intra-Cellular Therapies by 59.9% during the first quarter. Goldman Sachs Group Inc. now owns 133,184 shares of the biopharmaceutical company’s stock valued at $2,164,000 after acquiring an additional 49,884 shares in the last quarter. Hedge funds and other institutional investors own 71.79% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.